|
|
Article: Development of a pMDI formulation containing budesonide.(Proceedings of the Symposium on Advances in Pulmonary and Nasal Drug Delivery, October 2007, Mumbai)(pressurised metered dose inhalers)(Clinical report)
- Article from:
- Indian Journal of Pharmaceutical Sciences
- Article date:
- September 1, 2007
- Author:
CopyrightCOPYRIGHT 2007 Medknow Publications Pvt. Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: E. Robins, G. Brouet, S. Priolkar
A hydrofluoroalkane (HFA) based budesonide formulation was developed so that 220 [micro]g of budesonide per shot would exit the valve over 200 doses. This formulation was designed to be physically and chemically stable and it would give reproducible aerosol performances[sup] [1],[2],[3],[4] . The stability of the resulting metered dose inhaler was also evaluated under accelerated storage conditions (40[degrees]/75%RH) up to 6 mo. The aim was also to match the innovator Pulmicort[sup] [R] CFC (chlorofluorocarbon) product in terms of in vitro performances.
Materials and Methods
Excipients selected for ...